Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 27, 2026
DataAggregated Company Financials
Companies552
  • 7D-3.2%
  • 3M-0.8%
  • 1Y32.8%
  • YTD4.0%

Over the last 7 days, the Biotech industry has dropped 3.2%, driven by a pullback from AbbVie of 2.5%. In contrast, Inhibrx Biosciences has gained 57%. In the past year, the industry has gained 33%. Earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 27 Apr 2026US$1.3tUS$166.0b-US$11,982,883,986.9917.8x-108.4x7.8x
Wed, 25 Mar 2026US$1.3tUS$169.3b-US$15,116,425,731.1116.9x-83.4x7.4x
Fri, 20 Feb 2026US$1.3tUS$167.6b-US$13,402,775,963.6722x-100.1x8x
Sun, 18 Jan 2026US$1.2tUS$163.5b-US$15,150,311,707.6019.7x-80.8x7.5x
Tue, 16 Dec 2025US$1.2tUS$163.7b-US$15,629,182,813.9318.8x-78x7.4x
Thu, 13 Nov 2025US$1.2tUS$163.7b-US$16,361,101,083.0018.3x-72.3x7.2x
Sat, 11 Oct 2025US$1.2tUS$163.4b-US$18,215,346,855.4416.6x-63.1x7x
Mon, 08 Sep 2025US$1.1tUS$163.6b-US$18,346,659,491.1215.7x-58.9x6.6x
Wed, 06 Aug 2025US$1.0tUS$159.3b-US$15,865,734,075.2016.7x-65x6.5x
Fri, 04 Jul 2025US$960.1bUS$155.8b-US$23,422,935,456.9917.3x-41x6.2x
Sun, 01 Jun 2025US$908.1bUS$155.8b-US$23,980,173,787.0415.6x-37.9x5.8x
Tue, 29 Apr 2025US$784.0bUS$119.2b-US$31,078,506,586.1420.3x-25.2x6.6x
Thu, 27 Mar 2025US$827.3bUS$118.5b-US$36,884,032,976.2619.9x-22.4x7x
Sat, 22 Feb 2025US$863.3bUS$117.3b-US$37,606,528,073.3717x-23x7.4x
Mon, 20 Jan 2025US$947.4bUS$149.4b-US$26,286,185,460.0517.3x-36x6.3x
Wed, 18 Dec 2024US$996.7bUS$149.9b-US$26,485,748,422.0216.6x-37.6x6.6x
Fri, 15 Nov 2024US$1.1tUS$150.0b-US$27,266,729,255.6217.3x-39x7.1x
Sun, 13 Oct 2024US$902.0bUS$113.1b-US$36,040,263,614.5420.6x-25x8x
Tue, 10 Sep 2024US$894.1bUS$113.1b-US$35,658,177,880.3622.2x-25.1x7.9x
Thu, 08 Aug 2024US$1.2tUS$166.2b-US$32,645,503,888.5223.4x-35.8x7x
Sat, 06 Jul 2024US$1.1tUS$164.5b-US$28,073,491,589.9727.9x-39.9x6.8x
Mon, 03 Jun 2024US$1.1tUS$164.6b-US$26,677,143,877.6527.4x-42.1x6.8x
Wed, 01 May 2024US$1.1tUS$164.6b-US$27,373,262,846.2322.9x-39.5x6.6x
Fri, 29 Mar 2024US$1.2tUS$164.4b-US$23,753,804,933.9221.4x-49.6x7.2x
Sun, 25 Feb 2024US$1.2tUS$166.6b-US$21,694,949,476.2110.8x-54.3x7.1x
Tue, 23 Jan 2024US$1.4tUS$204.8b-US$22,505,965,323.0018.5x-63.5x7x
Thu, 21 Dec 2023US$1.4tUS$204.8b-US$22,158,313,482.0018.8x-61.2x6.6x
Sat, 18 Nov 2023US$1.2tUS$204.7b-US$22,079,363,558.0018.1x-54.7x5.9x
Mon, 16 Oct 2023US$1.3tUS$207.3b-US$13,079,327,258.0016.6x-96.8x6.1x
Wed, 13 Sep 2023US$1.3tUS$207.5b-US$12,640,460,182.0017.5x-101.7x6.2x
Fri, 11 Aug 2023US$1.3tUS$207.7b-US$12,610,114,686.0017.6x-101.5x6.2x
Sun, 09 Jul 2023US$1.1tUS$186.3b-US$16,022,507,026.0012.9x-69.1x5.9x
Tue, 06 Jun 2023US$1.1tUS$185.9b-US$16,008,078,695.0011.3x-71.1x6.1x
Thu, 04 May 2023US$1.2tUS$197.6b-US$7,506,497,270.0014.1x-154.8x5.9x
Price to Earnings Ratio

-154.8x


Total Market Cap: US$1.2tTotal Earnings: -US$7,506,497,270.00Total Revenue: US$197.6bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -57.9x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechs industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 7.8x.
Past Earnings Growth
  • The earnings for companies in the Biotechs industry have deteriorated over the last three years.
  • Revenues have also declined 5.6% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.33%
Healthcare-2.44%
Biotech-3.22%
Biotech-3.22%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
INBX Inhibrx BiosciencesUS$129.0656.7%
+US$681.8m		945.0%PS1450.1x
ARWR Arrowhead PharmaceuticalsUS$73.916.7%
+US$652.6m		446.7%PE51.2x
RCUS Arcus BiosciencesUS$25.5012.1%
+US$346.0m		209.1%PS12.9x
EXEL ExelixisUS$44.943.0%
+US$337.8m		16.9%PE14.6x
ANAB AnaptysBioUS$58.8815.6%
+US$228.0m		176.0%PS7.2x

Latest News

RCUS
US$25.50
Arcus Biosciences
7D
12.1%
1Y
209.1%

Arcus Biosciences: TIGIT In The Rearview Mirror, But Market Pricing A Bit Too Aggressively For Now

Apr 27
AMGN
US$344.55
Amgen
7D
-1.6%
1Y
21.7%
ARWR
US$73.91
Arrowhead Pharmaceuticals
7D
6.7%
1Y
446.7%
ANAB
US$58.88
AnaptysBio
7D
15.6%
1Y
176.0%
INBX
US$129.06
Inhibrx Biosciences
7D
56.7%
1Y
945.0%
RVMD
US$135.30
Revolution Medicines
7D
-7.5%
1Y
226.3%

Progress Against Pancreatic Cancer - Part 1

Apr 23
INSM
US$135.17
Insmed
7D
-5.4%
1Y
93.5%
ABBV
US$198.71
AbbVie
7D
-2.5%
1Y
3.3%

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.
GILD
US$130.40
Gilead Sciences
7D
-4.0%
1Y
22.6%
VRTX
US$430.29
Vertex Pharmaceuticals
7D
-2.0%
1Y
-13.3%

Vertex Pharmaceuticals: Looking For Signs Of Success In Q1 Earnings

Apr 22
EXEL
US$44.94
Exelixis
7D
3.0%
1Y
16.9%
TYRA
US$37.59
Tyra Biosciences
7D
9.4%
1Y
263.5%
BIIB
US$184.38
Biogen
7D
0.6%
1Y
54.8%

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.
ONC
US$300.80
BeOne Medicines
7D
-5.4%
1Y
20.6%
SMMT
US$22.08
Summit Therapeutics
7D
-12.1%
1Y
-8.4%
CPRX
US$27.37
Catalyst Pharmaceuticals
7D
5.0%
1Y
15.8%